Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Novacyt   /   Novacyt de volgende biotech raket!

Aandeel Novacyt PSE:ALNOV.FR, FR0010397232

Laatste koers (eur) Verschil Volume
0,670   +0,027   (+4,20%) Dagrange 0,649 - 0,687 252.264   Gem. (3M) 1,2M

Novacyt de volgende biotech raket!

Volgen
70.759 Posts
Pagina: «« 1 ... 3494 3495 3496 3497 3498 ... 3538 »» | Laatste | Omlaag ↓
  2. Speculatie 26 juli 2023 10:35
    quote:

    Speculatie schreef op 26 juli 2023 09:20:

    Als dat de reden is van de stijging, dan zie ik de koers vandaag wel weer zakken naar laag in de 70 en dan verder omlaag.
    Voda, je bent standvastig maar ik had gehoopt dat je onderhand al in kippen had geinvesteerd
    Onder de 70 zelfs met deze snelheid
  7. Crooswijk 27 juli 2023 08:45
    Sommige aandelen die we om 11.00 uur zullen bekijken op Taking Stock live zijn:

    Asos #ASC
    Deltische energie #DELT
    eEnergie #EAAS
    Novacyt SA #NCYT

    Als u wilt dat wij naar aandelen kijken, laat het ons dan weten via de onderstaande link ??
    youtube.com/watch?v=e9oSlV…

    @JohnHughman @VOXmarkets
  14. forum rang 10 DeZwarteRidder 27 juli 2023 17:11
    Novacyt S.A.

    ("Novacyt", the "Company" or the "Group")

    Half Year Trading Update

    Non-COVID sales growing quarter-on-quarter, significant progress in product development and non-organic growth strategy

    Paris, France and Eastleigh, UK - 27 July 2023 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its unaudited trading update for the six months ended 30 June 2023.

    Financial highlights

    · Group revenue for H1 2023 expected to be £3.3m of which £0.5m relates to COVID-19 (H1 2022: £16.5m of which £13.0m relates to COVID-19).

    · Revenue for non-COVID-19 portfolio of £2.8m representing 85% of total revenues (H1 2022: £3.5m). As previously signalled, H1 2022 is a high comparator particularly in instrumentation sales linked to COVID sales.

    · Non-COVID revenue continues to build with Q2 showing 3% growth over Q1 and 10% growth over Q4 2022.

    · Opex in H1 2023 is expected to be in the region of £7.1m, a reduction of c.13% vs H2 2022, reflecting restructuring plans implemented in Q4 2022.

    · Cash position at 30 June 2023 was £81.7m (H2 2022: £87.0m) and the Group remains debt free.

    Well positioned for diversified organic and non-organic growth

    Instrument sales have increased by over 65% in Q2 2023 compared with Q1 2023, showing signs of market improvement following the saturation that was seen during the COVID-19 pandemic, and non-COVID sales have increased incrementally over the last three quarters. The Company remains focused on building on the strength of its core business to deliver long-term sustainable growth, by expanding its product portfolio, driving international Research Use Only (RUO) sales and pursuing strategic business development opportunities. In line with this strategy, the Company announced on 3 July 2023 that it had made a recommended cash offer for Yourgene Health plc, an international integrated technologies and services business, enabling the delivery of genomic medicine. This is a key strategic milestone for Novacyt, which, upon anticipated completion by end of Q3 2023, will add scale and diversification to accelerate revenue growth and build long term value for the enlarged Group.

    Strong R&D progress

    During the period, the Company completed the development of six new multiplex RUO assays in the target therapeutic areas of gastrointestinal, respiratory, meningitis and other high-growth disease areas to meet the growing global demand for multiplex products that can detect multiple diseases in a single test. Management expects these products to begin commercialisation in the second half of 2023.

    On 29 June, the Company received its seventh UK Coronavirus Test Device Approval (CTDA) for its PathFlow® COVID-19 Rapid Antigen Self-Test.

    Focus on UKCA marking for UK clinical market

    Given the importance of the UK market for Novacyt's clinical diagnostics products, the Company will prioritise UK Conformity Assessed (UKCA) marking for a selection of its new multiplex tests. The UKCA mark is replacing the CE mark for all in vitro diagnostic (IVD) products sold in the UK. Under UKCA, IVD manufacturers can continue to self-certify their products, which typically takes six to nine months compared to 18 to 24 months to achieve a CE mark under the new European In Vitro Diagnostic Regulation (IVDR). The Company is planning to self-certify two of its new multiplex products for respiratory and insect-borne diseases during H2 2023, with a further four expected in 2024.

    In parallel, Novacyt is also progressing IVDR registration for its winter respiratory panel, genesig™ Real-time PCR SARS-CoV-2 Winterplex, which is expected to be completed by the end of 2024.

    James McCarthy, Acting Group CEO of Novacyt, commented: "We have remained focused on delivering our strategy during the first half and have made strong progress in expanding our internal product portfolio and diversifying our business away from COVID, as demonstrated by the Group's highly complementary proposed acquisition of Yourgene. The launch of six new multiplex tests for the RUO market has significantly broadened our IVD portfolio and gives us access to additional near term revenues. With the UKCA offering a more favourable regulatory pathway, we expect to start the self-certification process for two of these news tests during the second half of 2023 and expect them to be available for clinical use in the UK in H1 2024."
  16. forum rang 7 mvliex 1 28 juli 2023 14:45
    quote:

    DeZwarteRidder schreef op 28 juli 2023 12:49:

    [...]

    Het is wel verbazingwekkend dat sommige aandeelhouders van Novachit, zich eindeloos voor de gek laten houden door nep-shuffles.
    Daar jij het beter weet moet je hier ontzettend rijk van zijn geworden.....zo niet, dan geloof je er zelf dus niet in.
  20. forum rang 6 trab33 28 juli 2023 15:26
    quote:

    mvliex 1 schreef op 28 juli 2023 14:45:

    [...]Daar jij het beter weet moet je hier ontzettend rijk van zijn geworden.....zo niet, dan geloof je er zelf dus niet in.
    meestal wordt je er niet rijk van maar minder arm is ook al een groot voordeel . Dat is waar ik en zwarte ridder onervaren beleggers van willen behoeden
70.759 Posts
Pagina: «« 1 ... 3494 3495 3496 3497 3498 ... 3538 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee